| abstract |
REFERS TO COMPOUNDS OF FORMULA (I) WHERE R1 AND R2 ARE EACH H, HALOGEN, CN, C1-C6 ALKYL, AMONG OTHERS; R3 AND R4 ARE EACH H, OH, HALOGEN, NH2, AMONG OTHERS; Q1 IS A HETEROARYL OF 5 TO 10 MEMBERS, HETEROCICLOALKYL OF 4 TO 12 MEMBERS OR PHENYL; L1 IS O, S, C (= O), CH (OH), AMONG OTHERS; T1 IS H, OH, HALOGEN, CN, C1-C2 ALKYL; X1 IS O, S, NH, N (C1-C4 ALKYL), AMONG OTHERS; X2 IS NO C-T2; X3 IS NO C-T3; X4 IS N O C-T4, WHERE T2, T3 AND T4 ARE EACH H, OH, CN, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (+) - 1,5-DIMETHYL-6- [2-METHYL-4- (HAVE [3,2-d] PYRIMIDIN-4-ILOXI) PHENYL] PYRIMIDIN-2,4 (1H, 3H) -DIONA; 4,6-DIMETHYL-5- [2-METHYL-4 - ([1,2] THIAZOLO [5,4-c] PYRIDIN-7-ILOXI) PHENYL] PYRIDAZIN-3 (2H) -ONE; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE DOPAMINE D1 LIGANDS, BEING USEFUL IN THE TREATMENT OF SCHIZOPHRENIA, COGNITIVE DEFICIENCY, PARKINSON'S DISEASE, ANXIETY |